
## Prof. Dr. Dainius Characiejus Faculty of Medicine, Vilnius University dainius.characiejus@gmail.com



Dainius Characiejus got a M.D. degree from Vilnius University, Lithuania in 1980 and Ph.D. (equivalent) degree from the Research Institute of Oncology, Sankt-Petersburg, Russia in 1987. D. Characiejus was awarded Cancer Research Training Fellowship by the International Agency for Research on Cancer in 1988 and Yamagiwa-Yoshida Memorial International Cancer Study Grant by the International Union Against Cancer in 1993. During the tenure of these fellowships (1988 to 1989 and in 1994) he worked at Utrecht University, the Netherlands.

During 1980-2008 D. Characiejus worked at the Institute of Oncology in Vilnius as Junior Researcher, Senior Researcher and Deputy Director for Research. Presently, D. Characiejus is Professor of Pathophysiology and Immunology at Faculty of Medicine, Vilnius University. His recent research interests include prediction of response in cancer immunotherapy.

## Selected publications

Characiejus D, Jacobs JJ, Pašukonienė V, Kazlauskaitė N, Danilevičiūtė V, Mauricas M, Den Otter W. Prediction of response in cancer immunotherapy. *Anticancer Res* 31: 639-647, 2011

Characiejus D, Pašukonienė V, Jacobs JJ, Eidukevičius R, Jankevičius F, Dobrovolskienė N, Mauricas M, Van Moorselaar RJ, Den Otter W. Prognostic significance of peripheral blood CD8highCD57+ lymphocytes in bladder carcinoma patients after intravesical IL-2. *Anticancer Res* 31: 699-703, 2011

Jacobs JJL, Characiejus D, Pašukonienė V, Jankevičius F, Van Moorselaar RJA, Mauricas M, Den Otter W. Recurrences of superficial bladder carcinoma are associated with a raise of CD8highCD57+ and CD8low T lymphocytes in peripheral blood. *Open Cancer Immunol J* 3:8-14, 2010

Characiejus D, Hodzic J, Jacobs JJL. "First do no harm" and the importance of prediction in oncology. *EPMA J* 1:369–375, 2010

Jacobs JJ, Characiejus D, Scheper RJ, Stewart RJ, Tan JF, Tomova R, Krastev Z, Den Otter W. The Amiens Strategy: small phase III trials for clinically relevant progress in the war against cancer. *J Clin Oncol* 27:3062-3063, 2009

Characiejus D, Pašukonienė V, Jonušauskaitė R, Kazlauskaitė N, Aleknavičius E, Mauricas M, Den Otter W. Peripheral blood CD8highCD57+ lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha. *Anticancer Research* 28:1139-1142, 2008

Fervers B, Remy-Stockinger M, Mazeau-Woynar V, Otter R, Liberati A, Littlejohns P, Qureshi S, Vlayen J, Characiejus D et al. CoCanCPG. Coordination of cancer clinical practice in Europe. *Tumori* 94:154-159, 2008

Eidukevičius R, Characiejus D, Janavičius R, Kazlauskaitė N, Pašukonienė V, Mauricas M, Den Otter W. A method to estimate cell cycle time and growth fraction using bromodeoxyuridine-flow cytometry data from a single sample. *BMC Cancer* 5:122, 2005

Characiejus D, Pašukonienė V, Kazlauskaitė N, Valuckas KP, Petraitis T, Mauricas M, Den Otter W. Predictive value of CD8highCD57+ lymphocyte subset in interferon therapy of patients with renal cell carcinoma. *Anticancer Research* 22: 3679-3684, 2002